Israel Biosimilars Market (2025-2031) | Segmentation, Industry, Trends, Analysis, Size, Share, Outlook, Growth, Revenue, Forecast, Companies & Value

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Israel Country Macro Economic Indicators

3.2 Israel Biosimilars Market Revenues & Volume, 2021 & 2031F

3.3 Israel Biosimilars Market - Industry Life Cycle

3.4 Israel Biosimilars Market - Porter's Five Forces

3.5 Israel Biosimilars Market Revenues & Volume Share, By Product, 2021 & 2031F

3.6 Israel Biosimilars Market Revenues & Volume Share, By Indication, 2021 & 2031F

3.7 Israel Biosimilars Market Revenues & Volume Share, By Manufacturing, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of chronic diseases in Israel driving the demand for cost-effective treatment options like biosimilars.

4.2.2 Favorable government regulations and policies promoting the adoption of biosimilars in Israel.

4.2.3 Growing focus on research and development in the biopharmaceutical industry leading to the development of more biosimilar products.

4.3 Market Restraints

4.3.1 Limited awareness and understanding among healthcare professionals and patients about biosimilars.

4.3.2 High costs associated with the development and production of biosimilars impacting market growth.

4.3.3 Stringent regulatory requirements for the approval and commercialization of biosimilars in Israel.

6.1 Israel Biosimilars Market, By Product

6.1.1 Overview and Analysis

6.1.2 Israel Biosimilars Market Revenues & Volume, By Insulin, 2021-2031F

6.1.3 Israel Biosimilars Market Revenues & Volume, By Follitropin, 2021-2031F

6.1.4 Israel Biosimilars Market Revenues & Volume, By Calcitonin, 2021-2031F

6.1.5 Israel Biosimilars Market Revenues & Volume, By Glucagon, 2021-2031F

6.1.6 Israel Biosimilars Market Revenues & Volume, By Teriparatide, 2021-2031F

6.1.7 Israel Biosimilars Market Revenues & Volume, By Others, 2021-2031F

6.2 Israel Biosimilars Market, By Indication

6.2.1 Overview and Analysis

6.2.2 Israel Biosimilars Market Revenues & Volume, By Oncology, 2021-2031F

6.2.3 Israel Biosimilars Market Revenues & Volume, By Offsite Treatment, 2021-2031F

6.2.4 Israel Biosimilars Market Revenues & Volume, By Chronic Disorders, 2021-2031F

6.2.5 Israel Biosimilars Market Revenues & Volume, By Blood Disorders, 2021-2031F

6.2.6 Israel Biosimilars Market Revenues & Volume, By Infectious Diseases, 2021-2031F

6.2.7 Israel Biosimilars Market Revenues & Volume, By Others, 2021-2031F

6.3 Israel Biosimilars Market, By Manufacturing

6.3.1 Overview and Analysis

6.3.2 Israel Biosimilars Market Revenues & Volume, By Outsourced, 2021-2031F

6.3.3 Israel Biosimilars Market Revenues & Volume, By In-house, 2021-2031F

7.1 Israel Biosimilars Market Export to Major Countries

7.2 Israel Biosimilars Market Imports from Major Countries

8.1 Number of approved biosimilar products in the Israel market.

8.2 Adoption rate of biosimilars by healthcare providers and patients.

8.3 Investment in research and development of biosimilar products in Israel.

8.4 Rate of market penetration of biosimilars compared to originator biologics.

8.5 Number of partnerships and collaborations between biopharmaceutical companies in Israel for biosimilar development.

9.1 Israel Biosimilars Market Opportunity Assessment, By Product, 2021 & 2031F

9.2 Israel Biosimilars Market Opportunity Assessment, By Indication, 2021 & 2031F

9.3 Israel Biosimilars Market Opportunity Assessment, By Manufacturing, 2021 & 2031F

10.1 Israel Biosimilars Market Revenue Share, By Companies, 2024

10.2 Israel Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters